parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	group enriched in oligodendrocytes (359 nCPM)	1.00
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 17189

AMER2 in dopamine neurons, braak+0.47 (p 0.207) → -0.11 (p 0.787)receipt 17199
AMER2 in oligodendrocytes, braak+0.42 (p 0.262) → +0.34 (p 0.375)receipt 17198

receipt 17199: AMER2 in dopamine neurons, braak

power: full sample +0.15 (p 0.561, n 18), 95% CI -0.34 to +0.57. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.13 (p 0.603, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.37 (p 0.132, n 18). could be the mix.
skeptic: leave-one-out range +0.03 to +0.27, sign flips 0; without severely affected donors +0.15 (p 0.561, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for AMER2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 17198: AMER2 in oligodendrocytes, braak

power: full sample +0.27 (p 0.277, n 18), 95% CI -0.22 to +0.65. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.29 (p 0.250, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.16 (p 0.515, n 18). could be the mix.
skeptic: leave-one-out range +0.17 to +0.40, sign flips 0; without severely affected donors +0.27 (p 0.277, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for AMER2 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts